Stock Taper
GNTA
GENENTA SCIENCE S.P.A.
NASDAQ
$1.00
▲ UP 0.94% (0.01)

KEY STATISTICS

Market Cap$19.15 M
52w High$10.00
52w Low$0.55
Dividend Yield
Frequency
P/E-1.37
Volume57.76K
Shares Out.19.15M

COMPANY

LEADERSHIP

Pierluigi Paracchi
CHIEF EXECUTIVE
Pierluigi Paracchi

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 15, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
9

UPCOMING EARNINGS

DateSep 2, 2026
DayWednesday
Rev. Est.
SEP
2
WED

PRICE

$1.00 ▲ UP 0.94% (+$0.01)
$1.00$1.02$1.049:41 AM10:43 AM11:46 AM12:48 PM1:51 PM2:53 PM3:56 PM1.00

About Genenta Science S.p.A.

https://www.genenta.com ↗

Genenta Science S.p.A. is an Italy-based clinical-stage biotech developing hematopoietic stem cell gene therapies, including Temferon for glioblastoma and other solid tumors.

INDUSTRY

Biotechnology

A PRODUCT GENENTA SCIENCE S.P.A. IS KNOWN FOR

Temferon™
Temferon™

Temferon™ is a first-in-class hematopoietic stem cell gene therapy targeting solid tumors by delivering immune-therapeutic payloads within the tumor microenvironment, currently in clinical trials for glioblastoma and metastatic renal cell carcinoma.

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

DIRECTOR, 10 PERCENT OWNER, OFFICER: CHIEF EXECUTIVE OFFICER
Paracchi Pierluigi
Purchase · 100.0K shares
2026-03-30
DIRECTOR
PARACCHI GIACOMOANTONIO
Purchase · 20.0K shares
2026-03-30
DIRECTOR
Mutti Miguel Maria
Purchase · 20.0K shares
2026-03-30
OFFICER: CHIEF FINANCIAL OFFICER
SLANSKY RICHARD B
Purchase · 80.0K shares
2026-03-30

SECTORS PEERS

PEERPRICE
IPSC$2.02COMPARE
TELO$1.14COMPARE
INMB$2.33COMPARE
SER$2.46COMPARE
BRNS$0.75COMPARE
SKYE$1.77COMPARE
MDCX$0.26COMPARE
JUNS$4.18COMPARE